Titan Medical Inc (TMDIF)

[BigT82]

UPDATES / DUE DILIGENCE (DD) / NEWS LINKS FOR NEW AND CURRENT SHAREHOLDERS

June 26th, 2018 – Titan Medical’s CEO David McNally highlighted, along with Titan Medical

https://www.medtechstrategist.com/mts-blog/medtech-history-robotics-2

June 27th, 2018 – Titan Medical’s stock begins trading on NASDAQ

https://www.nasdaq.com/press-release/titan-medical-common-stock-to-trade-on-nasdaq-20180627-00275

June 28th, 2018 – Maxim Group initiates TMDI with a buy rating and $11 Price Target

https://www.streetinsider.com/Analyst+Comments/Maxim+Group+Starts+Titan+Medical+%28TMDI%29+at+Buy/14352426.html

June 28th, 2018 – Titan Medical appoints Medtech industry veteran Domenic Serafino to its BOD

https://globenewswire.com/news-release/2018/06/28/1530944/0/en/Titan-Medical-Appoints-Medtech-Industry-Veteran-Domenic-Serafino-to-Its-Board-of-Directors.html

June 28th, 2018 – Titan Medical Announces Marketed Offering of Units

https://titanmedicalinc.com/titan-medical-announces-marketed-offering-of-units/

Annual General Meeting (AGM) video link (2018 AGM should be live in the next week or two):

https://titanmedicalinc.com/investors/agm-information/

SPORT Product and SPORT Videos link:

https://titanmedicalinc.com/technology/#videos

Warrant Table as of June 14th, 2018

https://titanmedicalinc.com/investors/warrants/

As of June 27th, 2018 Titan Medical has ownership of 24 patents and 55 patent applications, with the anticipation of filing further patent applications in the future. Their Director of Strategic Development and Intellectual Property (IP), Jasminder Brar, has received numerous awards/recognition over the years. Here is his latest:

https://titanmedicalinc.com/titan-medicals-head-of-intellectual-property-recognized-as-a-global-ip-strategy-leader-by-intellectual-asset-management/

As you can see from the above, there are a lot of exciting things happening here, with plenty more on the way over the coming 12-24 months. Titan recently announced another capital raise on June 28th (link above) which should close on or around the 3rd or 4th week of this month (July 2018). Most of us all hope, and many believe, this could “potentially” be the final raise they will have to do before commercialization, as they should be able to net somewhere in the range of $20M-$27M now, and with the warrants attached would allow for another $23M-$31M once executed (assuming warrants are priced 15% higher). Furthermore, there is another $90M(ish) of warrant money that could flow into Titan’s coffers as the share price increases over the coming months / year. Titan has publicly announced they need a minimum of $52M more, through commercialization.

Where is the money going? See below, all found on SEDAR under the Preliminary short form prospectus dated June 28, 2018. https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00026560

As of 5/31/2018, the company had cash on hand of $26.4M from previous capital raises.

Q3 2018 and Q4 2018 milestones will continue the development of SPORT. These two will run about $25M.

Q1 2019 and Q2 2019 milestones will be documenting the results of the confidence build, implementing design improvements, schedule of preliminary audit of quality system by European Notified Body, as well as submit drafting of protocols to FDA in Q-submission(s) for comment. These will run about $27M.

The second half of 2019 will be the initiating of SPORT’s design freeze and ultimate submission for European CE Mark and 510(k) application to the FDA in late 2019. Costs TBD.

The above links and Titan’s website (https://titanmedicalinc.com/) are a great place to begin or continue your DD. I will try and keep the above current with moderator SPORT19’s help. Please DO NOT make any investment in this stock (or any stock for that matter) solely upon an anonymous investor board such as this one. Put in the time / DD and make a wise investment decision. Jump in when ready, as I believe Titan Medical has the management team in place that will put SPORT in an operating room near you come 2020. Oh, and deliver significant shareholder value in the process!